Most Read Articles
2 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

2 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
6 days ago
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Roshini Claire Anthony, 6 days ago

A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).

Olanzapine improves weight in adult outpatients with anorexia nervosa

12 Feb 2019

Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.

“Nevertheless, the finding on weight is notable, as achieving change in weight is notoriously challenging in this disorder,” the authors noted.

This randomized double-blind placebo-controlled trial conducted at five sites in North America assessed the benefits of olanzapine vs placebo for adult outpatients with anorexia nervosa.

A total of 152 participants (96 percent women; mean body mass index [BMI], 16.7 kg/m2) were randomly assigned in a 1:1 ratio to receive either olanzapine (n=75) or placebo (n=77). They were observed weekly for a 16-week period. The primary outcome measures were rates of change in body weight and change in obsessionality, assessed with the Yale-Brown Obsessive-Compulsive Scale (YBOCS).

Findings showed a statistically significant treatment-by-time interaction, which suggested that the increase in BMI over time was higher in patients in the olanzapine group (0.259 vs 0.095 per month) than in those in the placebo group.

No significant between-group difference was observed in change in the YBOCS obsessions subscale score over time (–0.325 vs –0.017 points per month). In addition, no significant between-group differences were seen in the frequency of abnormalities on blood tests assessing potential metabolic disturbances.

A small study in 2011 reported that olanzapine was more effective than placebo and was generally well tolerated by outpatients with anorexia nervosa. [Psychol Med 2011;41:2177-2182]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

2 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
6 days ago
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Roshini Claire Anthony, 6 days ago

A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).